Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NQO1 | P15559 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL613971 | 0.85 | SLC6A2 (0.50) | TSHRSLC6A2HTR2ASLC6A4HRH1 | |
| SCHEMBL12561575 | 0.83 | NQO1 (0.61) | TDP1TSHRNQO1SMN1; SMN2LMNA | |
| SCHEMBL21058263 | 0.81 | NQO1 (0.52) | TDP1TSHRNQO1SMN1; SMN2LMNA | |
| SCHEMBL13824185 | 0.80 | NQO1 (0.56) | TDP1TSHRNQO1SMN1; SMN2LMNA | |
| SCHEMBL19326408 | 0.80 | NQO1 (0.56) | TDP1TSHRNQO1SMN1; SMN2LMNA | |
| SCHEMBL183751 | 0.79 | SLC6A2 (0.57) | TDP1TSHRSLC6A2HTR2ASLC6A4 | |
| SCHEMBL30927804 | 0.79 | BLM (0.63) | TDP1TSHRNQO1SMN1; SMN2LMNA | |
| SCHEMBL8573749 | 0.79 | GAA (0.56) | TSHRSMN1; SMN2KDM4ETP53HSD17B10 | |
| SCHEMBL11579580 | 0.78 | SLC6A2 (0.66) | SLC6A2SLC6A3TAAR1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL3800374 | 0.78 | SLC6A2 (0.55) | TDP1SLC6A2HTR2ASLC6A4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562603-B3 | NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES | BOEHRINGER INGELHEIM PHARMA (DE) | 2014-01-08 | — | — | EP | disclosed |
| EP-1765355-B1 | BENZOXAZINE FOR TREATING RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-20120035169-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8044046-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2011-10-25 | — | — | US | disclosed |
| US-7786111-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-08-31 | — | — | US | disclosed |
| US-7727984-B2 | R-6-Hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino ]-ethyl}-4H-benzo[1,4]oxazin-3-one, or an acid addition salt thereof; betamimetics; for administration once a day for treating COPD | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2010-06-01 | — | — | US | disclosed |
| CN-101687875-A | Pyrrolopyrimidin-7-one derivatives and their use as pharmaceuticals | ASTRAZENECA AB | 2010-03-31 | — | — | CN | disclosed |
| EP-2155751-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-1562603-B1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20050272726-A1 | Novel medicaments for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-08 | — | — | US | disclosed |
| WO-2005110421-A2 | AEROSOL FORMULATION FOR INHALATION OF BETA AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256115-A1 | Aerosol formulation for the inhalation of beta-agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005102350-A1 | BENZOXAZINE FOR TREATING RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005102349-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | disclosed |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-06 | — | — | US | disclosed |
| EP-1562603-A2 | NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-08-17 | — | — | EP | disclosed |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-29 | — | — | US | disclosed |
| WO-2004045618-A2 | NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256115-A1 | Aerosol formulation for the inhalation of beta-agonists | ADRB1, ADRB2, ADRB3 | TDP1 3585/4885TSHR 505/4885NQO1 1582/4885 |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | MRGPRX2, MRGPRX1, CFTR | TDP1 3328/4885TSHR 2426/4885NQO1 797/4885 |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | TDP1 4590/4885TSHR 2408/4885NQO1 539/4885 |
| US-20050272726-A1 | Novel medicaments for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, CFTR | TDP1 3328/4885TSHR 2426/4885NQO1 797/4885 |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | CLIC1, OTC, SLC10A1 | TDP1 3219/4885TSHR 3787/4885NQO1 1812/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | TDP1 3763/4885TSHR 1866/4885NQO1 751/4885 |
| US-20120035169-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS | ADRB1, ADRB2, ADRB3 | TDP1 3585/4885TSHR 505/4885NQO1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.